

Financial Statements and Report of
Independent Certified Public
Accountants

The G. Unger Vetlesen Foundation

For the year ended December 31, 2021

Contents

	Page
Report of Independent Certified Public Accountants	3
Financial Statements	
Statement of assets and net assets arising from cash transactions	5
Statement of cash receipts, disbursements and change in net assets	6
Notes to financial statements	7
Supplemental Information	
Supplemental Schedule of Marketable Securities as of December 31, 2021 and 2020 and for the year ended December 31, 2021	15

GRANT THORNTON LLP

757 Third Avenue, 9th Floor
New York, NY 10017-2013

D +1 212 599 0100

F +1 212 370 4520

REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

To the Board of Directors of
The G. Unger Vetlesen Foundation

Opinion

We have audited the financial statements of The G. Unger Vetlesen Foundation (the "Foundation"), which comprise the statement of assets and net assets arising from cash transactions as of December 31, 2021, and the related statement of cash receipts, disbursements and changes in net assets for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the assets and net assets arising from cash transactions of the Foundation as of December 31, 2021, and the results of its cash receipts, disbursements and change in net assets for the year then ended in accordance with the cash basis of accounting described in Note 2.

Basis for opinion

We conducted our audit of the financial statements in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of matter – basis of accounting

We draw attention to Note 2 of the financial statements, which describes the basis of accounting. The financial statements are prepared on the cash basis of accounting, which is a basis of accounting other than accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to this matter.

Responsibilities of management for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the cash basis of accounting described in Note 2, and for determining that the cash basis of accounting is an acceptable basis for the preparation of the financial statements in the circumstances. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always

detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The Supplemental Schedule of Marketable Securities as of December 31, 2021 and 2020 and for the year ended December 31, 2021 on page 15 is presented for purposes of additional analysis and is not a required part of the financial statements. Such supplementary information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures. These additional procedures included comparing and reconciling the information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America established by the American Institute of Certified Public Accountants. In our opinion, the supplementary information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Grant Thornton LLP

New York, New York
November 21, 2022

The G. Unger Vetlesen Foundation

STATEMENT OF ASSETS AND NET ASSETS ARISING FROM CASH TRANSACTIONS

December 31, 2021

ASSETS

Cash and cash equivalents:

First Republic Bank checking account	\$ 118,693
Charles Schwab cash account	<u>5,329,991</u>

5,448,684

Marketable securities, at cost (Note 3):

Charles Schwab Common stocks (fair value \$210,807,742)	<u>55,226,736</u>
---	-------------------

Investments other, at cost:

Breakthrough LLC	999,837
Investment in FiscalNote	<u>555,978</u>

1,555,815

NET ASSETS WITHOUT DONOR RESTRICTION

\$ 62,231,235

The accompanying notes are an integral part of this financial statement.

The G. Unger Vetlesen Foundation

STATEMENT OF CASH RECEIPTS, DISBURSEMENTS AND CHANGE IN NET ASSETS

Year ended December 31, 2021

Cash receipts	
Dividends	
Common stock	\$ 2,832,501
Interest	
Deutsche Bank money market account	742
Charles Schwab money market account	347
Net realized gain on sale of marketable securities (net of investment fees \$471,286)	9,333,337
Capital gain distributions	56,229
Other income	3,439
	<hr/>
Total receipts	12,226,595
	<hr/>
Cash disbursements	
Grants (Note 5)	7,785,000
General and administrative expenses and taxes	325,260
	<hr/>
Total disbursements	8,110,260
	<hr/>
CHANGE IN NET ASSETS - EXCESS OF CASH RECEIPTS OVER DISBURSEMENTS	4,116,335
	<hr/>
Net assets, beginning of year	58,114,900
	<hr/>
Net assets, end of year	\$ 62,231,235
	<hr/> <hr/>

The accompanying notes are an integral part of this financial statement.

The G. Unger Vetlesen Foundation
NOTES TO FINANCIAL STATEMENTS

December 31, 2021

NOTE 1 - BUSINESS AND TAX STATUS

The G. Unger Vetlesen Foundation (the "Foundation") was incorporated on March 7, 1955, under the laws of the State of New York, as a nonprofit membership corporation for voluntarily aiding and contributing to religious, charitable, scientific, literary and educational uses and purposes, in New York, elsewhere in the United States and throughout the world. The funds of the Foundation may be expended for the purposes and objectives stated.

The Foundation is a tax-exempt organization pursuant to Section 501(c)(3) of the Internal Revenue Code, and, accordingly, is not subject to federal income tax. However, the Foundation is classified as a private foundation and, therefore, is subject to an annual federal excise tax of 1.39% on net investment income including dividends, interest and net realized gains on securities transactions, reduced by related expenses.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements and accounts of the Foundation are prepared on the basis of cash receipts and disbursements, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America ("US GAAP"); consequently, certain revenues, principally investment income, and related assets are recognized when received and expenses are recognized when paid. Under US GAAP, revenues and assets are recognized when earned and expenses and liabilities are recognized when the obligations are incurred. In addition, the Foundation reports marketable securities at cost rather than at fair value. Under US GAAP, marketable securities are reported at fair value.

Cash and Cash Equivalents

Cash and cash equivalents consist of bank checking accounts and money market funds. The Foundation considers all highly liquid financial instruments, with original maturities of three months or less from the date of purchase, to be cash equivalents.

Concentrations of Credit Risk

Cash and cash equivalents and investments are exposed to various risks, such as interest rate, market and credit. To minimize such risks, the Foundation has a diversified portfolio reviewed or managed by independent investment managers in a variety of asset classes. The Foundation regularly evaluates its investments, including performance thereof. Due to inherent risks and potential volatility in investment valuations, the amounts reported in the accompanying financial statements can vary substantially from year to year. The Foundation maintains its cash and cash equivalents in various bank deposit accounts which, at times, may exceed federally insured limits. The Foundation's cash accounts were placed with high-credit-quality financial institutions and, accordingly, the Foundation does not expect nonperformance.

Financial Statement Presentation

All assets and income are without donor restrictions as they are not restricted by donor-imposed restrictions and, therefore, are available for general operations of the Foundation.

The G. Unger Vetlesen Foundation

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021

NOTE 3 - MARKETABLE SECURITIES

Marketable securities are carried at cost in the accompanying financial statements. The cost basis of securities received from the Estate of George Unger Vetlesen, and the Palaemona Lyster Smythe Trust was determined based upon the related fair values as of the dates received, May 11, 1959 and January 3, 1985, respectively. The cost of securities sold is determined on the first-in, first-out cost basis.

The fair values of marketable securities are based on published closing prices on December 31, 2021. Changes in fair values of the marketable securities will affect future grants. At December 31, 2021, concentrations in marketable securities (5% or more of total fair value of marketable securities) included the following common stock investments at quoted market values:

Ametek Inc.	\$ 17,369,100
American Tower Corp CL A REIT	11,700,000
Microsoft Corp.	13,452,800
JP Morgan Chase & Co.	14,042,478
Nvidia Corp.	13,646,704
Roper Technologies	14,263,940
Thermo Fisher Scientific, Inc.	23,353,400
Union Pacific Corp.	<u>13,100,360</u>
	<u>\$ 120,928,782</u>

Since the financial statements of the Foundation are prepared on the basis of cash receipts and disbursements and therefore marketable securities are recorded at cost rather than at fair value, the Foundation has not applied the guidance relating to *Fair Value Measurements* to its financial statements, however, this guidance is still relevant for disclosure purposes. This guidance establishes a framework for measuring fair value, expands disclosures about fair value measurements and provides a consistent definition of fair value, which focuses on an exit price between market participants in an orderly transaction. The guidance also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information and establishes a three-level hierarchy for fair value measurements based on the transparency of information used in the valuation of an asset or liability as of the measurement date. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:

- Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The type of investments in Level 1 include listed equities held in the name of the Foundation, and exclude listed equities and other securities held indirectly through commingled funds.
- Level 2 - Pricing inputs, including broker quotes, are generally those other than exchange quoted prices in active markets, which are either directly or indirectly observable as of the measurement date, and fair value is determined through the use of models or other valuation methodologies.
- Level 3 - Pricing inputs are unobservable for the assets or liabilities and include situations where there is little, if any, market activity for the assets or liabilities. The inputs into the determination of fair value require significant management judgment or estimation.

In accordance with relevant guidance, the Foundation excludes investments valued using net asset value ("NAV") per share as a practical expedient from classification within the fair value hierarchy. The Foundation did not hold any investments valued at NAV per share as of December 31, 2021.

The G. Unger Vetlesen Foundation

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021

Inputs are used in applying the various valuation techniques and broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad credit data, liquidity statistics, and other factors. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. However, the determination of what constitutes "observable" requires significant judgment by the Foundation. The Foundation considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the Foundation's perceived risk of that instrument. As of December 31, 2021, all of the Foundation's investments were Level 1.

NOTE 4 - INVESTMENTS OTHER

Investments other represent net advances in partnerships and are carried at cost in the accompanying financial statements.

The Foundation entered into a partnership agreement with 8090 Breakthrough LLC, a Delaware limited liability company, as of March 4, 2021, for the purpose to invest (directly or indirectly) in shares or other securities of approximately fifteen issuers. The Foundation contributed \$1,020,000 of capital as a member during the year and had an ending capital account balance of \$999,837 as of December 31, 2021. Management fees paid during the year amounted to \$20,163. There were no withdrawals or distributions as of December 31, 2021.

The Foundation entered into a partnership agreement with 8090 FV LLC, a Delaware limited liability company, as of October 11, 2021, for the purpose to invest (directly or indirectly) in securities of FiscalNote Holdings, Inc. FiscalNote is a publicly traded company that has developed a software platform that uses artificial intelligence to deliver predictive analytics on government and legal policy. The Foundation contributed \$565,550 of capital as a member during the year and had an ending capital account balance of \$555,978 as of December 31, 2021. Management fees paid during the year amounted to \$9,572. There were no withdrawals or distributions as of December 31, 2021.

NOTE 5 - GRANTS

Grants paid in 2021 were as follows:

Organization	Purpose	Amount
American-Scandinavian Foundation	General purposes	\$ 25,000
Atlantic Salmon Federation	\$37,500 for general purposes and \$12,500 for Greenland project	50,000
Atlantic Salmon Trust	General purposes	50,000
Bermuda Institute of Ocean Sciences	General purposes	150,000
Bigelow Laboratory for Ocean Sciences	General purposes	150,000
Black Rock Forest Consortium	General purposes	50,000
Bonefish and Tarpon Trust	General purposes	50,000
Cape Eleuthera Foundation, Inc.	General purposes	50,000
Catholic Charities USA	Disaster relief operations	50,000

The G. Unger Vetlesen Foundation

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021

Organization	Purpose	Amount
Chesapeake Bay Foundation	\$25,000 for general purposes and \$50,000 for oyster restoration program	\$ 75,000
Colorado State University, Department of Atmospheric Science	Research on global temperature and Atlantic hurricanes	100,000
Trustees of Columbia University, Lamont-Doherty Earth Observatory	\$300,000 general purposes of the observatory; \$200,000 for programs of the Climate Center; and \$200,000 Vetlesen Prize	700,000
Connecticut Fund for the Environment	Save the Sound Program	50,000
Doctors Without Borders	International Medical Relief Programs	50,000
Game Conservancy USA	General purposes	35,000
Gulf of Maine Research Institute	Collaborative research efforts between GMRI scientists Lisa Kerr and Graham Sherwood and commercial fishermen, recreational anglers and aquaculture farms	100,000
International Yacht Restoration School	General purposes	25,000
Island Conservation	General purposes	50,000
Marine Biological Laboratories	\$350,000 to Dr. Sogin for the Bay Paul Center; and \$250,000 for the recruitment of Alexandra Z. Worden as Sr. Scientist at the Bay Paul Center	600,000
Massachusetts Institute of Technology	General purposes of the Joint Program on the Science and Policy of Global Change	100,000
National Parks Conservation Association	General purposes	25,000
Nature Conservancy of Idaho	General purposes	25,000
North Atlantic Salmon Fund	Campaign against sea cage salmon fishing in Iceland	25,000
Oregon State University, College of Earth, Ocean & Atmospheric Sciences	General purposes of the College of Earth, Ocean and Atmospheric Sciences	375,000
Organization for Tropical Studies	General purposes	50,000
Peregrine Fund	\$100,000 for visitor's center and \$100,000 for general purposes	200,000
Resources for the Future	Climate Economics and Policy Program	50,000
Rutgers University, School of Environmental and Biological Sciences	General purposes of the Center for Ocean Observing Leadership	150,000
Salvation Army	Disaster relief programs	50,000

The G. Unger Vetlesen Foundation

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021

Organization	Purpose	Amount
Scenic Hudson	Riverfront Communities Program and/or Ecological Restoration Initiatives	\$ 75,000
Sustainable Ocean Alliance	General purposes	50,000
Tall Timbers	General purposes	25,000
Texas A&M, Geochemical and Environmental Group	General purposes	50,000
UC San Diego Foundation, Scripps Institution of Oceanography	Global Change Program	600,000
University of British Columbia	\$50,000 for research on oceanic dead zones and \$50,000 for research on climate change and fisheries on salmon	100,000
University of Florida, Whitney Laboratory for Marine Biosciences	Center for Biological Imaging and Discovery	250,000
Univ. System of Maryland Foundation, Inst. of Marine and Environmental Technology	General purposes	100,000
University of Miami, Rosenstiel School of Marine and Atmospheric Science	General purposes	375,000
University of Rhode Island, Graduate School of Oceanography	General purposes	375,000
University of Texas, Institute for Geophysics	Antarctic Aerogeophysical Research Project	300,000
University of Virginia, Department of Civil and Environmental Engineering	Research on anthropogenic wastewater constituents to mitigate COVID-19	25,000
University of Washington, School of Oceanography	\$375,000 to the School of Oceanography, and \$25,000 to Dr. Laidre's work in Greenland	400,000
Webb Institute	General purposes	50,000
Wildlife Conservation Society	\$150,000 for general purposes; \$50,000 for Marine Program; \$50,000 for Wildlife Health Program; and \$500,000 for Bridge Fund	750,000
Woods Hole Oceanographic Institution	General purposes	750,000
Yellowstone Park Foundation	General purposes	50,000
Total		<u>\$ 7,785,000</u>

The G. Unger Vetlesen Foundation
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2021

At December 31, 2021, the Foundation had commitments to make future grants, aggregating \$650,000 as follows:

Organization	Purpose	Amount
Chesapeake Bay Foundation	Oyster restoration program	\$ 50,000
Marine Biological Laboratories	Recruitment at Josephine Bay Paul Center	250,000
Peregrine Fund	General purposes	100,000
University of Florida, Whitney Laboratory for Marine Bioscience	Center for Biological Imaging and Discovery	250,000
Total grants		<u>\$ 650,000</u>

NOTE 6 - RELATED PARTY TRANSACTIONS

Individual members of the Foundation's Board of Directors serve on the boards of directors or similar boards of a number of its grantees, including the Wildlife Conservation Society and the Peregrine Fund. None of the directors receive any compensation for their services as such.

NOTE 7 - FUNCTIONAL EXPENSES

For the year ended December 31, 2021, functional expenses were comprised of the following:

	Program Services	Management and General	Total
Grant expenditures	\$ 7,785,000	\$ -	\$ 7,785,000
Salaries and payroll taxes	183,979	45,995	229,974
Professional fees	50,484	12,621	63,104
Excise taxes	-	30,030	30,030
Miscellaneous	1,722	430	2,152
Total expenses	<u>\$ 8,021,185</u>	<u>\$ 89,076</u>	<u>\$ 8,110,260</u>

NOTE 8 - LIQUIDITY AND AVAILABILITY OF RESOURCES

The Foundation regularly monitors liquidity required to meet its operating needs, while also striving to maximize the investment of its portfolio. The Foundation has various sources of liquidity at its disposal, including cash and cash equivalents and marketable equity securities.

In addition to financial assets available to meet general expenditures over the next 12 months, the Foundation operates with a balanced budget and anticipates collecting sufficient investment portfolio returns to cover all of its grant making expenditures and operating needs.

The G. Unger Vetlesen Foundation
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2021

The Foundation's financial assets available within one year of December 31, 2021 for general expenditures are as follows:

Cash and cash equivalents	\$ 5,448,684
Marketable securities, fair value	<u>210,807,742</u>
	<u>\$ 216,256,426</u>

NOTE 9 - PANDEMIC IMPLICATIONS

In March of 2020 the World Health Organization officially declared COVID-19, a disease caused by the novel coronavirus, a pandemic. This caused many local and national governments, including New York State, to impose restrictions on business operations, travel and time spent outside the home. The outbreak has adversely impacted the level of economic activity around the world and disrupted normal business activity in every sector of the economy. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. External factors, including the duration and intensity of the pandemic, the shape of the economic recovery across the globe, as well as timing and widespread adoption of vaccines, may have an impact on the Foundation's operating results. Due to the many uncertainties associated with the pandemic, management is unable to determine the full magnitude it may have on the Foundation's financial condition, liquidity and future results.

NOTE 10 - SUBSEQUENT EVENTS

The Foundation evaluated its December 31, 2021 financial statements for subsequent events through November 21, 2022, the date the financial statements were available to be issued.

SUPPLEMENTAL INFORMATION

The G. Unger Vetlesen Foundation

SUPPLEMENTAL SCHEDULE OF MARKETABLE SECURITIES

As of December 31, 2021 and 2020 and for the year ended December 31, 2021

Common Stocks	Held at December 31, 2020		Additions		Sales and Other Dispositions				Held at December 31, 2021			Dividends Received in 2021	Capital Gain 2021
	Shares or Principal Amount	Cost Basis	Shares or Principal Amount	Cost Basis	Shares or Principal Amount	Cost Basis	Proceeds	Gain (loss)	Shares or Principal Amount	Cost Basis	Fair Value 12/31/2021		
Abbott Laboratories	-	\$ -	14,000	\$ 1,776,138	-	\$ -	\$ -	\$ -	14,000	\$ 1,776,138	\$ 1,970,360	\$ -	\$ -
Adaptive Biotechnologies Corp	70,000	2,537,669	-	-	-	-	-	-	70,000	2,537,669	1,964,200	-	-
Adobe Inc	3,000	919,714	2,000	1,149,547	-	-	-	-	5,000	2,069,261	2,835,300	-	-
American Tower Corp CL A REIT	40,000	1,696,777	-	-	-	-	-	-	40,000	1,696,777	11,700,000	201,200	-
Ametek Inc.	118,125	1,608,102	-	-	-	-	-	-	118,125	1,608,102	17,369,100	94,500	-
Bio Techne Corp	20,200	3,061,966	-	-	-	-	-	-	20,200	3,061,966	10,450,268	25,856	-
Boeing Company	7,500	996,176	-	-	-	-	-	-	7,500	996,176	1,509,900	-	-
Biomarin Pharmaceutical Inc.	25,000	2,174,093	-	-	25,000	2,174,093	1,994,922	(179,171)	-	-	-	-	-
Bristol Meyers Squibb Co.	75,000	4,192,500	-	-	30,000	1,677,000	1,787,967	110,967	45,000	2,515,500	2,805,750	147,000	-
CooperCo	16,000	2,135,750	-	-	-	-	-	-	16,000	2,135,750	6,703,040	960	-
CrowdStrike Holdings Inc	-	-	2,000	498,100	-	-	-	-	2,000	498,100	409,500	-	-
Exxon Mobil Corp.	100,000	381,310	-	-	-	-	-	-	100,000	381,310	6,119,000	349,000	-
Fidelity National Information Service	15,500	2,154,645	-	-	-	-	-	-	15,500	2,154,645	1,691,825	24,180	-
Global Payments Inc	24,000	2,568,080	-	-	-	-	-	-	24,000	2,568,080	3,244,320	21,360	-
Guardant Health Inc	34,000	1,788,857	-	-	-	-	-	-	34,000	1,788,857	3,400,680	-	-
Idexx Corp	9,000	1,582,620	-	-	2,000	385,623	978,182	592,559	7,000	1,196,997	4,609,220	-	-
Illumina Inc	3,500	1,087,635	-	-	-	-	-	-	3,500	1,087,635	1,331,540	-	-
International Flavors & Fragrances	13,559	7,642	-	-	-	-	-	-	13,559	7,642	2,042,663	42,106	-
JP Morgan Chase & Co.	88,680	1,909,796	-	-	-	-	-	-	88,680	1,909,796	14,042,478	328,116	-
Merck & Co. Inc.	134,000	165,579	-	-	15,000	25,456	1,232,072	1,206,616	119,000	140,123	9,120,160	348,400	-
Microsoft Corp.	40,000	1,866,265	-	-	-	-	-	-	40,000	1,866,265	13,452,800	92,000	-
Murphy Oil Corp.	200,000	660,922	-	-	-	-	-	-	200,000	660,922	5,222,000	100,000	-
Nvidia Corp	11,600	2,057,800	-	-	-	-	-	-	11,600	2,057,800	13,646,704	7,424	-
Organon & Co	-	-	13,400	7,793	13,400	7,793	390,139	382,346	-	-	-	-	-
Parker Hannifin Corp	25,000	2,488,518	-	-	-	-	-	-	25,000	2,488,518	7,953,000	99,250	-
PotlatchDeltic Corp	100,471	451,952	-	-	-	-	-	-	100,471	451,952	6,050,364	513,442	56,229
Roper Technologies	34,000	4,243,219	-	-	5,000	698,660	1,930,169	1,231,509	29,000	3,544,559	14,263,940	68,063	-
Sage Therapeutics Inc.	19,600	2,010,173	-	-	-	-	-	-	19,600	2,010,173	833,784	-	-
ServiceNow Inc.	1,800	956,512	1,800	878,725	-	-	-	-	3,600	1,835,237	2,336,796	-	-
Teleflex Inc	4,500	1,549,440	-	-	-	-	-	-	4,500	1,549,440	1,478,160	6,120	-
TE Connectivity LTD	20,000	2,008,842	-	-	-	-	-	-	20,000	2,008,842	3,226,800	39,600	-
Thermo Fisher Scientific, Inc.	40,000	3,360,203	-	-	5,000	365,848	2,927,808	2,561,960	35,000	2,994,355	23,353,400	40,000	-
Twilio Inc	-	-	4,000	1,455,762	-	-	-	-	4,000	1,455,762	1,053,360	-	-
Union Pacific Corp.	72,000	1,148,463	-	-	20,000	319,018	4,216,855	3,897,837	52,000	829,445	13,100,360	274,580	-
Visa Inc. CL A Com	7,000	1,342,942	-	-	-	-	-	-	7,000	1,342,942	1,516,970	9,345	-
		<u>\$ 55,114,162</u>		<u>\$ 5,766,065</u>		<u>\$ 5,653,491</u>	<u>\$ 15,458,114</u>	<u>\$ 9,804,623</u>		<u>\$ 55,226,736</u>	<u>\$ 210,807,742</u>	<u>\$ 2,832,501</u>	<u>\$ 56,229</u>

This supplemental schedule should be read in conjunction with the accompanying financial statements and notes thereto.